Lipocine starts new Phase 3 trial for postpartum depression drug

September 14, 2026 8:00 AM

Lipocine Inc. (NASDAQ: LPCN) announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154, an oral formulation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found